研究单位：[1]Peking University Cancer Hospital & Institute[2]BeiGene[3]Anhui Provincial Hospital,Hefei,Anhui,China,230000[4]Beijing Cancer Hospital,Beijing,Beijing,China,100142[5]Chongqing Cancer Hospital,Chongqing,Chongqing,China,400030[6]Fujian Medical University Union Hospital,Fuzhou,Fujian,China,350001[7]Affiliated Hospital of Hebei University,Baoding,Hebei,China,071000[8]Harbin Medical University Cancer Hospital,Harbin,Heilongjiang,China,150000[9]Henan Cancer Hospital,Zhengzhou,Henan,China,450000[10]Jilin Cancer Hospital,Changchun,Jilin,China,130021[11]Affiliated Zhongshan Hospital of Fudan University,Shanghai,Shanghai,China,200032[12]Zhejiang University College of Medicine Second Affiliated Hospital,Hangzhou,Zhejiang,China,310009[13]Zhejiang Cancer Hospital,Hangzhou,Zhejiang,China,310022
In this Phase 2, Single-Arm, Multi-Center, Open-Label Study, participants with previously treated locally advanced unresectable or metastatic solid tumors with mismatched repair deficient (dMMR) or microsatellite instability-high (MSI-H) will be treated with anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317).
